EVALUATION OF UVEITIS ACTIVITY USING BOS24 IN PATIENTS WITH BEHСET'S DISEASE
https://doi.org/10.14412/1995-4484-2016-681-686
Abstract
Objective: to estimate changes of uveitis activity using BOS24 (Behсet's disease Ocular attack Score 24) during antiinflammatory and immunosuppressive therapy in patients with Behcet's disease (BD).
Subjects and methods. 103 (75.6%) of the 138 patients with BD fulfilled the 1990 International Study Group for Behсet's Disease (ISGBD) criteria had eye lesions; 55 (53.4%) of the 103 patients had an exacerbation of uveitis. 55 patients with an exacerbation of uveitis were found to have active inflammation in 94 eyes. The activity of uveitis was monitored during anti-inflammatory and immunosuppressive therapy, by using BOS24 that consists of 6 parameters with maximal possible value 24.
Results and discussion. The mean BOS24 for 94 eyes with active uveitis at baseline was 9.33±0.91. The most pronounced inflammatory changes were found in the posterior chamber of the eye, mainly in the area of the peripheral retina, rarely in the area of the fovea and in the optic disc. All the patients with an exacerbation of uveitis received systemic therapy with glucocorticoids, cyclosporine and/or azathioprine. After 8.92±3.47 months of treatment, the mean BOS2 decreased significantly (p < 0.001) to 2.20±1.02. The most substantial positive changes were noted in the anterior chamber of the eye (p = 0.03), vitreous humor (p < 0.01), and peripheral retina (p < 0.001).
Conclusion. BOS24 is a reliable tool to quantify uveitis activity in patients with BD and its dynamics during antiinflammatory and immunosuppressive therapy.
About the Authors
T. A. Lisitsyna
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
G. A. Davydova
Helmholtz Moscow Research Institute of Eye Diseases, Ministry of Health of Russia
Russian Federation
14/19, Sadovaya- Chernogryazskaya St., Moscow 105062
Russian Federation
14/19, Sadovaya- Chernogryazskaya St., Moscow 105062
Z. R. Khatagova
Helmholtz Moscow Research Institute of Eye Diseases, Ministry of Health of Russia
Russian Federation
14/19, Sadovaya- Chernogryazskaya St., Moscow 105062
Russian Federation
14/19, Sadovaya- Chernogryazskaya St., Moscow 105062
L. A. Katargina
Helmholtz Moscow Research Institute of Eye Diseases, Ministry of Health of Russia
Russian Federation
Russian Federation
14/19, Sadovaya- Chernogryazskaya St., Moscow 105062
Z. S. Alekberova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Алекберова ЗС. Болезнь Бехчета: монография. Москва; 2007. 86 с. [Alekberova ZS. Bolezn' Bekhcheta [Behcet’s disease]. Moscow; 2007. 86 p.].
2. Nussenblatt RB. Uveitis in Behcet's disease. Int Rev Immunol. 1997;14(1):67-79. doi: 10.3109/08830189709116845
3. Tugal-Tuktun I, Onal S, Altan-Yaycioglu R. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373-80. doi: 10.1016/j.ajo.2004.03.022
4. Ohguro N, Sonoda KH, Takeuchi M, et al. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432-5. doi: 10.1007/s10384-012-0158-z
5. Kaburaki T, Namba K, Sonoda KH, et al; Ocular Behcet Disease Research Group of Japan. Behcet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014 Mar;58(2):120-30. doi: 10.1007/s10384-013-0294-0
6. Hatemi G, Silman A, Bang D, et al. Management of Behcet's disease: a systematic literature review for the EULAR evidence based recommendations for the management of Behcet's disease. Ann Rheum Dis. 2008;67:1656-62. doi: 10.1136/ard.2008.087957
7. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-8.
8. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358:295-6. doi: 10.1016/s0140-6736(01)05497- 6
9. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology. 2007;46:1161-4. doi: 10.1093/rheumatology/kem101
10. Hazirolan D, StЯbiger N, Pleyer U. Light on the Horizont: biologicals in Behcet uveitis. Acta Ophthalmol. 2013;91:297-306. doi: 10.1111/j.1755-3768.2011.02348.x
11. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye. 2007;21:824-5. doi: 10.1038/sj.eye.6702352
12. Benitah NR, Sobrin L, Papaliodis GN. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Semin Ophthalmol. 2011 Jul-Sep;26 (4-5):295- 303. doi: 10.3109/08820538.2011.588665
13. Calvo Catala J, Campos Fernandez C, Rueda Cid A, et al. Efficacy of adalimumab in Behcet's disease. Description of 6 cases. Reumatol Clin. 2011;7(4):258-61. doi: 10.1016/s2173-5743(11)70056-9
14. Bhakta BB, Brennan P, James TE, et al. Behcet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38:728-33. doi: 10.1093/rheumatology/38.8.728
15. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet's disease activity index. Rheumatology (Oxford). 2004;43:73-8. doi: 10.1093/rheumatology/keg453
16. International Study Group for Behcet's Disease. Criteria for diagnosis of Behсet's disease. Lancet. 1990;335:1078-80. doi: 10.1016/0140-736(90)92643-V
17. Zouboulis Ch, Vaiopoulos G, Macromichelakis N, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behcet's disease in Greece. Clin Exp Rheum. 2003;21 Suppl 30:S19-26.
18. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509-16. doi: 10.1016/j.ajo.2005.03.057
19. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467- 71. doi: 10.1016/s0161-6420(85)34001-0
20. Okada AA, Goto H, Ohno S, Mochizuki M; Ocular Behcet's Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;130:592-8. doi: 10.1001/archophthalmol.2011.2698
Review
For citations:
Lisitsyna T.A., Davydova G.A., Khatagova Z.R., Katargina L.A., Alekberova Z.S. EVALUATION OF UVEITIS ACTIVITY USING BOS24 IN PATIENTS WITH BEHСET'S DISEASE. Rheumatology Science and Practice. 2016;54(6):681-686. (In Russ.) https://doi.org/10.14412/1995-4484-2016-681-686
Views:
628
Email this article 